IPA
Price
$0.37
Change
+$0.03 (+8.82%)
Updated
Apr 4, 04:11 PM (EDT)
Capitalization
15.56M
ITRM
Price
$1.14
Change
-$0.03 (-2.56%)
Updated
Apr 4, 04:29 PM (EDT)
Capitalization
40.81M
35 days until earnings call
Ad is loading...

IPA vs ITRM

Header iconIPA vs ITRM Comparison
Open Charts IPA vs ITRMBanner chart's image
ImmunoPrecise Antibodies
Price$0.37
Change+$0.03 (+8.82%)
Volume$1.5K
Capitalization15.56M
Iterum Therapeutics
Price$1.14
Change-$0.03 (-2.56%)
Volume$784
Capitalization40.81M
IPA vs ITRM Comparison Chart
Loading...
IPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ITRM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IPA vs. ITRM commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IPA is a Hold and ITRM is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (IPA: $0.34 vs. ITRM: $1.17)
Brand notoriety: IPA and ITRM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IPA: 15% vs. ITRM: 50%
Market capitalization -- IPA: $15.56M vs. ITRM: $40.81M
IPA [@Biotechnology] is valued at $15.56M. ITRM’s [@Biotechnology] market capitalization is $40.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IPA’s FA Score shows that 1 FA rating(s) are green whileITRM’s FA Score has 1 green FA rating(s).

  • IPA’s FA Score: 1 green, 4 red.
  • ITRM’s FA Score: 1 green, 4 red.
According to our system of comparison, both IPA and ITRM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IPA’s TA Score shows that 4 TA indicator(s) are bullish while ITRM’s TA Score has 4 bullish TA indicator(s).

  • IPA’s TA Score: 4 bullish, 4 bearish.
  • ITRM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both IPA and ITRM are a good buy in the short-term.

Price Growth

IPA (@Biotechnology) experienced а -22.78% price change this week, while ITRM (@Biotechnology) price change was -9.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.20%. For the same industry, the average monthly price growth was -17.06%, and the average quarterly price growth was -18.80%.

Reported Earning Dates

ITRM is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (-11.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ITRM($40.8M) has a higher market cap than IPA($15.6M). IPA YTD gains are higher at: -17.416 vs. ITRM (-33.898). ITRM has higher annual earnings (EBITDA): -21.73M vs. IPA (-24.28M). ITRM has more cash in the bank: 24.1M vs. IPA (3.53M). IPA has less debt than ITRM: IPA (16.4M) vs ITRM (45.5M). IPA has higher revenues than ITRM: IPA (24.1M) vs ITRM (0).
IPAITRMIPA / ITRM
Capitalization15.6M40.8M38%
EBITDA-24.28M-21.73M112%
Gain YTD-17.416-33.89851%
P/E RatioN/AN/A-
Revenue24.1M0-
Total Cash3.53M24.1M15%
Total Debt16.4M45.5M36%
FUNDAMENTALS RATINGS
IPA vs ITRM: Fundamental Ratings
IPA
ITRM
OUTLOOK RATING
1..100
3059
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6363
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IPA's Valuation (21) in the null industry is significantly better than the same rating for ITRM (88) in the Biotechnology industry. This means that IPA’s stock grew significantly faster than ITRM’s over the last 12 months.

IPA's Profit vs Risk Rating (100) in the null industry is in the same range as ITRM (100) in the Biotechnology industry. This means that IPA’s stock grew similarly to ITRM’s over the last 12 months.

IPA's SMR Rating (98) in the null industry is in the same range as ITRM (100) in the Biotechnology industry. This means that IPA’s stock grew similarly to ITRM’s over the last 12 months.

IPA's Price Growth Rating (63) in the null industry is in the same range as ITRM (63) in the Biotechnology industry. This means that IPA’s stock grew similarly to ITRM’s over the last 12 months.

ITRM's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for IPA (100) in the null industry. This means that ITRM’s stock grew significantly faster than IPA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IPAITRM
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 19 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
IPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ITRM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EVI17.730.16
+0.91%
EVI Industries
BRFS3.470.03
+0.87%
BRF - Brasil Foods SA
MSI435.50-1.49
-0.34%
Motorola Solutions
GEL14.82-1.14
-7.14%
Genesis Energy LP
PRLD0.71-0.08
-10.05%
Prelude Therapeutics